USD 0.16
(0.65%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 99.82 Million USD | -16.63% |
2022 | 119.73 Million USD | 28.31% |
2021 | 93.31 Million USD | 114.27% |
2020 | 43.55 Million USD | 35.33% |
2019 | 32.18 Million USD | 3144.05% |
2018 | 992 Thousand USD | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q1 | 20.14 Million USD | -3.06% |
2024 Q2 | 45.15 Million USD | 124.21% |
2023 Q2 | 26.13 Million USD | -1.47% |
2023 Q1 | 26.52 Million USD | 8.98% |
2023 FY | 99.6 Million USD | -16.82% |
2023 Q3 | 26.33 Million USD | 0.8% |
2023 Q4 | 20.77 Million USD | -21.12% |
2022 Q4 | 24.33 Million USD | -17.05% |
2022 Q3 | 29.33 Million USD | -22.53% |
2022 Q2 | 37.87 Million USD | 34.33% |
2022 Q1 | 28.19 Million USD | -4.79% |
2022 FY | 119.73 Million USD | 28.31% |
2021 Q4 | 29.6 Million USD | 29.92% |
2021 FY | 93.31 Million USD | 114.27% |
2021 Q1 | 20.48 Million USD | 48.78% |
2021 Q3 | 22.79 Million USD | 11.53% |
2021 Q2 | 20.43 Million USD | -0.24% |
2020 Q2 | 9.01 Million USD | -2.2% |
2020 FY | 43.55 Million USD | 35.33% |
2020 Q4 | 13.76 Million USD | 19.24% |
2020 Q3 | 11.54 Million USD | 28.05% |
2020 Q1 | 9.22 Million USD | -13.38% |
2019 Q2 | 8 Million USD | 0.0% |
2019 Q4 | 10.64 Million USD | 92.48% |
2019 Q3 | 5.53 Million USD | -30.91% |
2019 FY | 32.18 Million USD | 3144.05% |
2019 Q1 | 8 Million USD | 0.0% |
2018 FY | 992 Thousand USD | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
ADC Therapeutics SA | 233.01 Million USD | 57.161% |
Alto Neuroscience, Inc. | 37.8 Million USD | -164.017% |
Annovis Bio, Inc. | 45.03 Million USD | -121.654% |
Biohaven Pharmaceutical Holding Company Ltd. | 436.05 Million USD | 77.108% |
Ginkgo Bioworks Holdings, Inc. | 1.1 Billion USD | 90.994% |
Nuvation Bio Inc. | 99.82 Million USD | 0.0% |
Arcus Biosciences, Inc. | 457 Million USD | 78.157% |
Theriva Biologics, Inc. | 21.43 Million USD | -365.783% |
Zymeworks Inc. | 196.76 Million USD | 49.267% |